TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02243982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [F18]-FDDNP
Description: radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
Study: NCT01826838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 1.1 Primary Objective 1.1.1 To evaluate the maximum tolerated dose and dose limiting toxicities of dasatinib, up to a dose of 100mg/day, with concurrent standard radiation and hormone therapy for patients with intermediate and high risk prostate cancer.~1.2 Secondary Objective: 1.2.1 To determine the time to progression and overall survival for patients who are diagnosed with Intermediate and High Risk Prostate Cancer and were treated with dasatinib.
Study: NCT03510923

Intervention type: OTHER
Intervention: Inspection and palpation of the appendix
Description: The removed appendix will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The appendix will not be opened. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the appendix, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.

Intervention type: OTHER
Intervention: Inspection and palpation of the gallbladder
Description: The removed gallbladder will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The gallbladder is opened in its length, without cutting the cystic duct, and is inspected and palpated. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the gallbladder, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
Study: NCT02818790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Bodyguard + Precious App. Short onsite training session on how to use the system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Bodyguard + Precious App + Motivational Interviewing. Face to face counseling session followed by a short onsite training session on how to use the system.
Study: NCT01853722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCN01
Description: Three serial applications per periocular region.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unisol
Description: Three serial applications per periocular region.
Study: NCT02589366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphoseek plus Vital Blue Dye
Description: intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
Study: NCT02294305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02061280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol 250/50 Dry Powder Inhaler
Description: Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol 250/50 Dry Powder Inhaler
Description: Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol 100/50 Dry Powder Inhaler
Description: Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol 100/50 Dry Powder Inhaler
Description: Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone 100mcg Dry Powder Inhaler
Description: Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone 100mcg Dry Powder Inhaler
Description: Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization
Study: NCT03785262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uroshield
Description: The Uroshield device sends out low-frequency ultrasound waves which run along the surface of the catheter.
Study: NCT03121339

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-A1.1 H1 Tablet Vaccine (small)
Description: Tableted oral H1 vaccine (\~140 mg tablet)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-A1.1 H1 Tablet Vaccine (small)
Description: Tableted oral H1 vaccine (\~140 mg tablet)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-A1.1 H1 Tablet Vaccine (large)
Description: Tableted oral H1 vaccine (\~275 mg tablet)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-A1.1 H1 Tablet Vaccine (large)
Description: Tableted oral H1 vaccine (\~275 mg tablet)
Study: NCT02744001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Added Sugar Diet
Description: 1-week intake of Low Added Sugar Diet 3 day rotating menu
Study: NCT04144218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: The experimental group will be given oral lacosamide supplementation on the basis of the original antiepileptic drugs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
Study: NCT04250311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMH-407
Description: MMH-407: For oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: For oral use.
Study: NCT03431103

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: 12 week home exercise program
Study: NCT04213573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silver diamine fluoride
Description: 38% silver diamine fluoride liquid will be applied with a brush

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MI Varnish
Description: topical fluoride varnish with calcium and phosphate
Study: NCT03351985

Intervention type: DEVICE
Intervention: quantitative electroencephalogram (qEEG)
Description: the patients receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU

Intervention type: DEVICE
Intervention: quantitative electroencephalogram (qEEG)
Description: the patients receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
Study: NCT03817502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules, oral administration, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules, oral administration, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, oral administration, once daily.
Study: NCT04120805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostatic Agent
Description: Patients undergoing robotic-assisted laparoscopic partial nephrectomy with the use of hemostatic agents by a surgeon

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Hemostatic Agent
Description: Patients undergoing robotic-assisted laparoscopic partial nephrectomy without the use of hemostatic agents by a surgeon
Study: NCT04487717

Intervention type: DEVICE
Intervention: nProfiler I Stomach Cancer Assay Kit
Description: nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
Study: NCT03785262

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Uroshield
Description: The sham Uroshield device is identical to the active machine, but it does not send out low-frequency ultrasound waves along the surface of the catheter.
Study: NCT01664767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulfur Thermal water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02120677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
Study: NCT01090505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: S-1 and oxaliplatin
Description: Drug:S-1:80mg/m2;oxaliplatin 130mg/m2

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Drug: S-1 and oxaliplatin
Description: Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
Study: NCT04585815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab Prefilled syringe
Description: prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: solution supplied in vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-TGT
Description: solution in vials
Study: NCT02275416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Study: NCT03927768

Intervention type: DIAGNOSTIC_TEST
Intervention: Predictive Model
Description: Anonymized, post-processed MRI imaging data will be analyzed to construct a model predicting benign vs malignant lesions. Model will be tested on a second cohort.

Intervention type: DIAGNOSTIC_TEST
Intervention: Predictive Model
Description: Anonymized, post-processed MRI imaging data will be analyzed to construct a model predicting benign vs malignant lesions. Model will be tested on a second cohort.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Imagers
Description: Anonymized research sequence with the addition of modeling data (Aims 1A and 1B) will be read by three blinded breast imagers and final evaluation compared to the full protocol.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Imagers
Description: Anonymized research sequence with the addition of modeling data (Aims 1A and 1B) will be read by three blinded breast imagers and final evaluation compared to the full protocol.
Study: NCT02313896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone calls
Description: Phone calls from medical staff assess confusion of the patient, and recommend immediate changes to dosage of lactulose.
Study: NCT02092818

Intervention type: DRUG
Intervention: Riociguat (Adempas, BAY63-2521)
Description: The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)
Study: NCT03944980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD1-T cells
Description: PD1-T cells injection
Study: NCT02451813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apposition of needle bevel against femoral nerve
Description: Indentation of femoral nerve and fascia iliaca by block needle and measurement of opening injection pressure during the controlled injection of 1 ml of dextrose (D5W) solution
Study: NCT02506621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: R test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nuubo
Study: NCT02708251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyceryl trinitrate cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Study: NCT03856320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: An educational video describing obesity treatment options available in the VA.
Study: NCT03073850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet
Description: ASA or clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose oral anticoagulant
Description: Edoxaban of 30mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose oral anticoagulant
Description: Edoxaban of 60mg
Study: NCT02975700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: 1000 mg/day (400 mg in the morning and 600 mg in the evening)
Study: NCT02657551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
Study: NCT01369654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized decision aid with 1 type of value clarification
Description: Women will be instructed to view a computerized BSO decision support guide.
Study: NCT01541202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNRG-1
Description: 10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
Study: NCT00957385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revlimid
Description: 10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.
Study: NCT02309619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.
Description: Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.
Description: Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.
Study: NCT02467881

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Increase (GLB-MOD)
Description: The Group Lifestyle Balance (GLB) program was adapted from the original DPP lifestyle intervention. As in the original DPP lifestyle program, the GLB goals are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes/week of moderately intense physical activity similar to a brisk walk.~The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sedentary Time Decrease (GLB-SED)
Description: As in the original DPP, the GLB goal for weight is to achieve and maintain a 7% weight loss. For this intervention arm, instead of focusing on increasing moderate physical activity, the GLB curriculum will be adapted to address decreasing sitting time. Participants will have a goal of decreasing sitting time by 45 minutes/day. The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression.

Intervention type: OTHER
Group type: OTHER
Intervention: 6-month delayed (DELAYED)
Description: Individuals assigned to 6 month delay will wait for 6 months from baseline to be randomly assigned to one of the two interventions and will begin intervention at that time. During the waiting period they will receive health information newsletters.
Study: NCT01817452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study: NCT03995511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Sagittal Split Osteotomy
Description: Surgical correction of lower jaw deformity by performing bilateral intraoral sagittal osteotomy of the mandible under general anesthesia.
Study: NCT01624207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: generic formulation of atorvastatin (Atorva®)
Description: Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: branded formulation of atorvastatin (Lipitor®)
Description: Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
Study: NCT04360655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoscopic microwave intervention
Description: bronchoscopic microwave intervention
Study: NCT01969123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: EVP-6124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: EVP-6124
Study: NCT04360655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
Description: anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
Study: NCT03462563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTERCEED™
Description: when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
Study: NCT02819544

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride administration
Description: Sodium chloride administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine administration
Description: Ropivacaine administration
Study: NCT01284088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex™ device for adult male circumcision
Description: The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical circumcision
Description: The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
Study: NCT04360655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
Description: anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
Study: NCT00782431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vero cell derived, trivalent, seasonal influenza vaccine
Description: Single intramuscular injection
Study: NCT02614066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.
Study: NCT01969123

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02614066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.
Study: NCT00782431

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed egg-derived, trivalent seasonal influenza vaccine
Description: Single intramuscular injection
Study: NCT01418560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic modification
Description: Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure